Every year in the U.S., about a million people are treated at emergency rooms for traumatic brain injuries (TBIs), and about ...

Eclipse Life Sciences begins phase 2 study for novel ophthalmology steroid implant for diabetic macular edema: Research Triangle Park, North Carolina Tuesday, April 14, 2026, 18:0 ...

Eclipse Life Sciences, Inc., a privately held clinical-stage biopharmaceutical company focused on the development of novel therapies for ophthalmic diseases, today announced that it has completed ...

The FDA’s decision to extend the labeled duration of faricimab use in RVO beyond 6 months primarily reflects accumulated ...

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced publication of the results from the NEW DAY ...

Approval is based on 96-week data from 2 pivotal trials showing majority of EYLEA HD patients maintained their visual and anatomic improvements ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of a pivotal Phase 2b ...

If you have dry age-related macular degeneration, your central vision may end up blurry, distorted or dim.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today results from two Phase III studies evaluating the efficacy and safety ...

(RTTNews) - Roche has announced encouraging results from two Phase III clinical trials evaluating the investigational drug vamikibart (0.25 mg and 1 mg doses) for the treatment of uveitic macular ...

– Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may offer a potential new treatment option for patients – – Vision improvements were seen in ...